- Home
- EDRY vs ANTX Comparison
EDRY vs ANTX Comparison
Compare EDRY & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- ANTX
- Stock Information
- Founded
- EDRY 2018
- ANTX 2017
- Country
- EDRY Greece
- ANTX United States
- Employees
- EDRY N/A
- ANTX N/A
- Industry
- EDRY Marine Transportation
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- ANTX Health Care
- Exchange
- EDRY Nasdaq
- ANTX Nasdaq
- Market Cap
- EDRY 35.3M
- ANTX 34.4M
- IPO Year
- EDRY N/A
- ANTX 2022
- Fundamental
- Price
- EDRY $12.54
- ANTX $1.19
- Analyst Decision
- EDRY
- ANTX Buy
- Analyst Count
- EDRY 0
- ANTX 2
- Target Price
- EDRY N/A
- ANTX $2.00
- AVG Volume (30 Days)
- EDRY 2.6K
- ANTX 45.6K
- Earning Date
- EDRY 11-18-2025
- ANTX 11-12-2025
- Dividend Yield
- EDRY N/A
- ANTX N/A
- EPS Growth
- EDRY N/A
- ANTX N/A
- EPS
- EDRY N/A
- ANTX N/A
- Revenue
- EDRY $49,707,775.00
- ANTX N/A
- Revenue This Year
- EDRY N/A
- ANTX N/A
- Revenue Next Year
- EDRY $20.65
- ANTX N/A
- P/E Ratio
- EDRY N/A
- ANTX N/A
- Revenue Growth
- EDRY N/A
- ANTX N/A
- 52 Week Low
- EDRY $7.60
- ANTX $0.98
- 52 Week High
- EDRY $19.64
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- EDRY 56.95
- ANTX 43.96
- Support Level
- EDRY $12.11
- ANTX $1.18
- Resistance Level
- EDRY $12.57
- ANTX $1.30
- Average True Range (ATR)
- EDRY 0.26
- ANTX 0.07
- MACD
- EDRY -0.08
- ANTX -0.02
- Stochastic Oscillator
- EDRY 55.28
- ANTX 30.00
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.